Market Overview The global market size for cardiac resynchronization therapy systems reached USD 4.28 billion in 2022 and is projected to reach USD 7.35 billion by 2032, with a forecasted revenue compound annual growth rate (CAGR) of 7%.

Regional Outlook: North America is anticipated to hold the highest share of the global CRT market due to the increasing prevalence of cardiac disorders in the region. The availability of sophisticated healthcare infrastructure and growing patient awareness of CRT system benefits are expected to contribute to market expansion. Favorable healthcare policies and reimbursement plans further support the growth of the CRT market in North America.

Competitive Landscape: Key companies in the global cardiac resynchronization therapy system market include Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, St. Jude Medical Inc. (Abbott Laboratories), Biotronik SE & Co. KG, and LivaNova PLC.

Strategic developments among major players include Medtronic plc’s introduction of the AdaptivCRT algorithm in 2020, aimed at providing personalized therapy to patients. Abbott Laboratories received authorization for its HeartMate 3 Left Ventricular Assist Device in Japan in 2019, intended to enhance cardiac function in patients with advanced heart failure.

The prevalence of cardiovascular disorders such as heart failure, atrial fibrillation, and ventricular tachycardia is increasing worldwide. The American Heart Association estimates that 6.2 million Americans are currently experiencing heart failure, a number expected to rise to 8 million by 2030. This escalating prevalence has led to a growing demand for cardiac resynchronization therapy systems, which have proven effective in improving cardiac function and enhancing the quality of life for heart failure patients.

Get a sample copy of the Cardiac Resynchronization Therapy System Market report:

Factors such as the emphasis on precision medicine, personalized treatment regimens, and the integration of Artificial Intelligence (AI) in healthcare are expected to propel the global cardiac resynchronization therapy system market. AI-powered systems can analyze extensive patient data, providing tailored treatment recommendations that enhance patient outcomes and reduce the risk of adverse events.

The adoption of telemedicine and home healthcare services is anticipated to create new opportunities for market participants. The demand for cardiac resynchronization therapy systems is expected to rise due to increased interest in remote cardiac function monitoring and diagnosis.

Product Types Analysis: The market is segmented into CRT-P (CRT Pacemakers) and CRT-D (CRT Defibrillators) based on product type. In 2022, the CRT-D segment dominated the market due to the increasing prevalence of heart failure and cardiovascular disorders globally. CRT-D devices, equipped with defibrillation features, are effective in addressing aberrant heart rhythms and reducing the risk of sudden cardiac death. The segment is expected to continue experiencing revenue growth.

End-Use Analysis: Hospitals, clinics, and ambulatory surgical centers (ASCs) constitute the three end-use segments of the CRT market. In 2022, hospitals accounted for the highest revenue share, attributed to the large patient volume and the availability of advanced medical infrastructure. CRT systems, requiring specific implantation techniques and aftercare, are typically administered in hospitals by qualified medical staff. The budget allocation for cutting-edge medical technology in hospitals further encourages the utilization of CRT systems.

Clinics are expected to experience a considerable CAGR during the forecast period, driven by the increasing popularity of outpatient procedures and therapies. Clinics offer practical and cost-effective alternatives to hospitals, making them more accessible to patients. The demand for CRT systems in clinics is anticipated to rise with the widespread use of telemedicine and Remote Patient Monitoring technologies.

ASCs are also expected to witness significant expansion during the forecast period, fueled by the growing preference for minimally invasive procedures and the emphasis on healthcare cost containment and efficiency. The popularity of outpatient operations is anticipated to boost demand for CRT systems in ASCs, providing patients with cost-effective options and shorter hospital stays.

New product launches include Medtronic plc’s introduction of the Percepta Quad CRT-P system in 2021, offering individualized and adaptable therapy for heart failure patients. St. Jude Medical, Inc. (Abbott Laboratories) launched the Quadra Assura MPTM CRT-D device in 2020, aiming to improve patients’ quality of life and cardiac function.

Market Segmentation: The global cardiac resynchronization therapy system market is segmented based on product type (CRT-P and CRT-D), end-use (hospitals, clinics, and ambulatory surgical centers), and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa).

Explore Trending Reports:

Natural Rubber Market-

Automotive Repair & Maintenance Service Market-

Automotive Alternative Propulsion Market-

Request a customization of the report:

Thank you for reading our report. To know more about the customization or any query about the report contents, please connect with us and our team will ensure the report is tailored to meet your requirements.

About Reports and Data    

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W

(Head of Business Development)

Reports and Data | Web:

Direct Line: +1-212-710-1370

E-mail: [email protected]

Blogs | Press Release | Industry News | Our competencies

Browse More Upcoming Reports @

Browse More Latest Reports @

Browse Latest Blogs:

Browse Latest Press Release: